LLY•benzinga•
Rznomics Enters Global Licensing Agreement With Eli Lilly For RNA-editing Therapeutics; If Lilly Exercises All Available Options Under The Agreement, The Total Deal Value Could Reach More Than $1.3B, As Well As Separate Royalties On Product Sales; The Upf
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 15, 2025 by benzinga